Palvella Therapeutics (PVLA) Price & Analysis

Compare

667 Followers

PVLA Stock Chart & Stats

$73.15

-$0.34(-2.31%)

At close: Jan 08 4:00 PM EST

$73.15

-$0.34(-2.31%)

Day’s Range― - ―

52-Week Range$11.17 - $77.67

Previous CloseN/A

Volume11.83K

Average Volume (3M)198.60K

Market Cap

$808.90M

Enterprise Value$193.21M

Total Cash (Recent Filing)$70.43M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Apr 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.86

Shares Outstanding11,059,665

10 Day Avg. Volume233,795

30 Day Avg. Volume198,599

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.43

Price to Sales (P/S)0.00

P/FCF Ratio-2.46

Enterprise Value/Market Cap0.24

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-12.81

Forecast

1Y Price Target

$79.75

Price Target Upside9.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Market OpportunityAdding another indication and expanding the addressable market for QTORIN rapamycin by approximately 40% provides further opportunity to validate its use in multiple mTOR driven diseases.

Physician Adoption96% of surveyed physicians indicated they would incorporate an approved 3.9% w/w topical rapamycin into their practice in treating CSAs.

Bears Say

Regulatory ChallengesThere are no FDA approved treatments for CSA, and current standard of care options are invasive, inadequate, and can cause pain, scarring, and lesion recurrence.

Palvella Therapeutics News

Palvella received second year of funding under its FDA Office of OPD grant

Palvella Therapeutics (PVLA) announced it has received the second year of funding under its FDA Office of Orphan...

5d ago

PVLA

Palvella Therapeutics price target raised to $90 from $66 at Canaccord

Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $90 from $66 and keeps a Buy...

9d ago

PVLA

Palvella Therapeutics price target raised to $120 from $70 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Palvella Therapeutics (PVLA) to $120 from $70 and keeps an...

11d ago

PVLA

Palvella Therapeutics price target raised to $80 from $56 at Truist

Truist analyst Danielle Brill raised the firm’s price target on Palvella Therapeutics (PVLA) to $80 from $56 and...

16d ago

PVLA

Palvella Therapeutics price target raised to $95 from $75 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $95 from $75 and keeps a...

23d ago

PVLA

Palvella Therapeutics price target raised to $80 from $60 at Stifel

Stifel analyst Annabel Samimy raised the firm’s price target on Palvella Therapeutics (PVLA) to $80 from $60 and...

24d ago

PVLA

Palvella Therapeutics expands QTORIN rapamycin development program

Palvella Therapeutics (PVLA) announced the expansion of its QTORIN 3.9% rapamycin anhydrous gel development program into Clinically Significant...

24d ago

PVLA

Positive Buy Rating for Palvella Therapeutics Driven by Promising CVM Treatment and Market Potential

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of...

10d ago

PVLA

Palvella Expands QTORIN Gel Program for Rare Disease

Palvella Therapeutics ( ($PVLA) ) has shared an update. On September 24, 2025, Palvella Therapeutics announced the expansion...

23d ago

PVLA

Buy Rating for Palvella Therapeutics Driven by Strategic Expansion of QTORIN Rapamycin for Unmet CSA Treatment

TD Cowen analyst Ritu Baral has maintained their bullish stance on PVLA stock, giving a Buy rating yesterday....

23d ago

PVLA

Palvella Therapeutics: Expanding Market Potential with QTORIN 3.9% Rapamycin for Angiokeratomas

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with...

24d ago

PVLA

Buy Rating for Palvella Therapeutics: Innovative QTORIN 3.9% Rapamycin Gel Addresses Unmet Needs in Venous Malformations

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with...

1M ago

PVLA

Palvella Therapeutics announces publication of literature review of rapamycin

Palvella Therapeutics (PVLA) announced the publication of a manuscript in Lymphatic Research and Biology which summarizes a systematic...

1M ago

PVLA

Optimistic Buy Rating for Palvella Therapeutics Amid Promising Trial Developments and Market Potential

In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with...

1M ago

PVLA

PVLA FAQ

What was Palvella Therapeutics’s price range in the past 12 months?

Palvella Therapeutics lowest stock price was $11.17 and its highest was $77.67 in the past 12 months.

What is Palvella Therapeutics’s market cap?

Palvella Therapeutics’s market cap is $808.90M.

When is Palvella Therapeutics’s upcoming earnings report date?

Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 170 days.

How were Palvella Therapeutics’s earnings last quarter?

Palvella Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.741 by -$0.119.

Is Palvella Therapeutics overvalued?

According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics pay dividends?

Palvella Therapeutics does not currently pay dividends.

What is Palvella Therapeutics’s EPS estimate?

Palvella Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Palvella Therapeutics have?

Palvella Therapeutics has 11,059,665 shares outstanding.

What happened to Palvella Therapeutics’s price movement after its last earnings report?

Palvella Therapeutics reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.741. Following the earnings report the stock price went up 3.271%.

Which hedge fund is a major shareholder of Palvella Therapeutics?

Currently, no hedge funds are holding shares in PVLA

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-68.21%

Trailing 12-Months

Asset Growth

194.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palvella Therapeutics

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.

Palvella Therapeutics (PVLA) Earnings & Revenues

Historic Earnings Reports

PVLA Company Deck

PVLA Earnings Call

Q2 2025

0:00 / 0:00

PVLA Stock 12 Month Forecast

Average Price Target

$79.75

▲(9.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","84":"$84","157":"$157","230":"$230","303":"$303"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$79.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$50.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,84,157,230,303],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.23,67.59692307692308,71.96384615384615,76.33076923076923,80.69769230769231,85.0646153846154,89.43153846153847,93.79846153846154,98.16538461538462,102.5323076923077,106.89923076923077,111.26615384615386,115.63307692307693,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.23,64.50076923076922,65.77153846153846,67.04230769230769,68.31307692307692,69.58384615384615,70.85461538461539,72.12538461538462,73.39615384615385,74.66692307692307,75.9376923076923,77.20846153846153,78.47923076923077,{"y":79.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.23,62.21230769230769,61.19461538461538,60.176923076923075,59.15923076923077,58.14153846153846,57.12384615384615,56.106153846153845,55.08846153846154,54.07076923076923,53.05307692307692,52.035384615384615,51.01769230769231,{"y":50,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":302.4,"date":1640995200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >